Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe‐Elie Salem; Ali Manouchehri; Melissa Moey; Bénédicte Lebrun‐Vignes; Lisa Bastarache; Alexandre Pariente; Aurélien Gobert; Jean‐Philippe Spano; Justin M. Balko; Marc P. Bonaca; Dan M. Roden; Douglas B. Johnson; Javid J. Moslehi

doi:10.1016/s1470-2045(18)30608-9

Keywords

PharmacovigilanceMedicineMedDRAAdverse effectInternal medicineOdds ratioObservational studyRetrospective cohort studyAdverse Event Reporting SystemDatabaseIntensive care medicineEmergency medicine

Affiliated Institutions

Related Publications

A review of cancer immunotherapy toxicity

Lucy Boyce Kennedy , April K.S. Salama

Abstract Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies ha...

2020 CA A Cancer Journal for Clinicians 1364 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Rimda Wanchoo , Sabine Karam , Nupur N. Uppal +5 more

<b><i>Background:</i></b> Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has...

2017 American Journal of Nephrology 15268 citations

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden , Danny Rischin , Chrysalyne D. Schmults +34 more

Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usua...

2018 New England Journal of Medicine 1322 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins , Sofiya Latifyan , Gerasimos P. Sykiotis +14 more

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-...

2019 Nature Reviews Clinical Oncology 2064 citations

Publication Info

Year: 2018
Type: article
Volume: 19
Issue: 12
Pages: 1579-1589
Citations: 1091
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1091

OpenAlex

Cite This

APA Style

                            
                                
                                    Joe‐Elie Salem, 
                                
                                    Ali Manouchehri, 
                                
                                    Melissa Moey
                                
                                et al.
                            
                            (2018). 
                            Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. 
                            The Lancet Oncology
                            , 19
                            (12)
                            , 1579-1589.
                            https://doi.org/10.1016/s1470-2045(18)30608-9
                        

Identifiers

DOI: 10.1016/s1470-2045(18)30608-9